Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 13/20 | 0.47 |
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196519 | 0.88 | GPR52 (0.47) | S1PR5GPR52S1PR4 | |
| SCHEMBL13489559 | 0.86 | GPR52 (0.65) | S1PR5GPR52 | |
| SCHEMBL1849767 | 0.86 | GPR52 (0.48) | S1PR5GPR52S1PR4PLA2G2A | |
| SCHEMBL1857402 | 0.83 | GPR52 (0.50) | S1PR5GPR52S1PR4 | |
| SCHEMBL1848475 | 0.81 | S1PR5 (0.49) | S1PR5GPR52S1PR4FOLH1PLA2G2A | |
| SCHEMBL1850213 | 0.80 | GPR52 (0.54) | S1PR5GPR52S1PR4PLA2G2A | |
| SCHEMBL1851263 | 0.80 | S1PR5 (0.43) | S1PR5GPR52S1PR4FOLH1 | |
| SCHEMBL1848035 | 0.79 | GPR52 (0.53) | S1PR5GPR52S1PR4FOLH1PLA2G2A | |
| SCHEMBL1852762 | 0.77 | GPR52 (0.54) | S1PR5GPR52S1PR4PLA2G2A | |
| SCHEMBL1846891 | 0.77 | S1PR5 (0.53) | S1PR5GPR52S1PR4FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | S1PR5 696/4885GPR52 1/4885S1PR4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.